7th November 2024, Mumbai: Alembic Pharmaceuticals Limited reported its consolidated financial results for the second quarter ended 30th September 2024.
Financial Highlights
- Net Sales increased by 3% to Rs.1648 Crores.
- EBITDA up 18% to Rs. 257 Crores
- EBITDA Margin at 15.6% of Sales
- Net Profit up 12% to Rs.153 Crores.
Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “India’s Branded Business continues to enhance execution capabilities in both quality and scale, with the Specialty and Animal Health segments showing good growth. The USFDA successfully inspected our Oncology Formulation Facility (F-2) without any form 483 observations.”
Operational Highlights
India Branded Business
- India Branded Business grew 6% to Rs. 609 Crores for the quarter.
- Recorded good growths in specialty therapies like 8% in Gynaecology, 11% in Cardiology, 18% in Anti Diabetic and 13% in Ophthalmology therapies.
- Animal Health business grew 20% for the quarter with basket of strong brands driving outperformance.
- 3 launches during the quarter. New launches continue to do well along with promising future launches across key segments.
International Business
- US Generics grew 5% to Rs. 467 Crores for the quarter.
- 8 Launches in the US market during the quarter.
- Ex-US International Formulations grew 18% to Rs. 298 Crores for the quarter.
- 9 ANDA approvals received during the quarter, 214 Cumulative ANDA approvals.
API Business
- API business at Rs. 274 Crores for the quarter.
The summary of Total Revenue is as under:
(Rs in Crores)
| Particulars | Q2 FY25 | Q2 FY24 | % Change | H-1 FY25 | H-1 FY24 | % Change |
| Formulation | ||||||
| India | 609 | 577 | 6% | 1181 | 1101 | 7% |
| USA
Ex- US |
467
298 |
444
252 |
5%
18% |
928
568 |
834
518 |
11%
10% |
| API | 274 | 322 | (15%) | 532 | 628 | (15%) |
| Total | 1648 | 1595 | 3% | 3210 | 3081 | 4% |